The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

about

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Item

http://www.wikidata.org/entity/Q45215365

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@en

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@nl

type

Item

label

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@en

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@nl

prefLabel

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@en

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@nl

P1476

The prognostic value of CT rad ...... FR tyrosine kinase inhibitors.

@en

P2093

Bhumsuk Keam

http://www.w3.org/2001/XMLSchema#string

Chang Min Park

http://www.w3.org/2001/XMLSchema#string

Dae Seog Heo

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

Hyungjin Kim

http://www.w3.org/2001/XMLSchema#string

Miso Kim

http://www.w3.org/2001/XMLSchema#string

Sang Joon Park

http://www.w3.org/2001/XMLSchema#string

Tae Min Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Measuring Computed Tomography Scanner Variability of Radiomics Features

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors

P304

e0187500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0187500

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jin Mo Goo

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29099855

http://www.w3.org/2001/XMLSchema#string

P932

5669442

http://www.w3.org/2001/XMLSchema#string